共 49 条
Myocardial Flow Reserve, an Independent Prognostic Marker of All-Cause Mortality Assessed by 82Rb PET Myocardial Perfusion Imaging: A Danish Multicenter Study
被引:6
|作者:
Hojstrup, Signe
[1
,2
,4
]
Hansen, Kim W.
[2
,4
]
Talleruphuus, Ulrik
[3
,5
]
Marner, Lisbeth
[3
,5
]
Bjerking, Louise
[2
]
Jakobsen, Lars
[6
]
Christiansen, Evald H.
[6
]
Bouchelouche, Kirsten
[7
,8
]
Wiinberg, Niels
[3
,5
]
Guldbrandsen, Kasper
[3
,5
,9
]
Galatius, Soren
[2
,4
]
Prescott, Eva
[2
,4
]
机构:
[1] Copenhagen Univ Hosp, Dept Cardiol, Bispebjerg & Frederiksberg, Nordre Fasanvej 57, Vej 4, 3, DK-2000 Frederiksberg, Denmark
[2] Copenhagen Univ Hosp, Dept Cardiol, Bispebjerg, Denmark
[3] Copenhagen Univ Hosp, Dept Clin Physiol & Nucl Med, Bispebjerg, Denmark
[4] Copenhagen Univ Hosp, Dept Cardiol, Frederiksberg, Denmark
[5] Copenhagen Univ Hosp, Dept Clin Physiol & Nucl Med, Frederiksberg, Denmark
[6] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark
[7] Aarhus Univ Hosp, Dept Nucl Med, Aarhus, Denmark
[8] Aarhus Univ Hosp, PET Ctr, Aarhus, Denmark
[9] Rigshosp, Copenhagen Univ Hosp, Dept Clin Physiol Nucl Med & PET, Copenhagen, Denmark
关键词:
coronary circulation;
microcirculation;
myocardial perfusion imaging;
positron-emission tomography;
Rubidium-82;
survival;
POSITRON-EMISSION-TOMOGRAPHY;
CORONARY-ARTERY-DISEASE;
BLOOD-FLOW;
MICROVASCULAR DYSFUNCTION;
REPRODUCIBILITY;
QUANTIFICATION;
ACCURACY;
D O I:
10.1161/CIRCIMAGING.122.015184
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
BACKGROUND:Rubidium-82 positron emission tomography (Rb-82 PET) myocardial perfusion imaging is used in clinical practice to quantify regional perfusion defects. Additionally, Rb-82 PET provides a measure of absolute myocardial flow reserve (MFR), describing the vasculature state of health. We assessed whether Rb-82 PET-derived MFR is associated with all-cause mortality independently of the extent of perfusion defects. METHODS:We conducted a multicenter clinical registry-based study of patients undergoing Rb-82 PET myocardial perfusion imaging on suspicion of chronic coronary syndromes. Patients were followed up in national registries for the primary outcome of all-cause mortality. Global MFR & LE;2 was considered reduced. RESULTS:Among 7169 patients studied, 38.1% were women, the median age was 69 (IQR, 61-76) years, and 39.0% had MFR & LE;2. A total of 667 (9.3%) patients died during a median follow-up of 3.1 (IQR, 2.6-4.0) years, more in patients with MFR & LE;2 versus MFR >2 (15.7% versus 5.2%; P<0.001). MFR & LE;2 was associated with all-cause mortality across subgroups defined by the extent of perfusion defects (all P<0.05). In a Cox survival regression model adjusting for sex, age, comorbidities, kidney function, left ventricular ejection fraction, and perfusion defects, MFR & LE;2 was a robust predictor of mortality with a hazard ratio of 1.62 (95% CI, 1.31-2.02; P<0.001). Among patients with no reversible perfusion defects (n=3101), MFR & LE;2 remained strongly associated with mortality (hazard ratio, 1.86 [95% CI, 1.26-2.73]; P<0.01). The prognostic value of impaired MFR was similar for cardiac and noncardiac death. CONCLUSIONS:MFR & LE;2 predicts all-cause mortality independently of the extent of perfusion defects. Our results support the inclusion of MFR when assessing the prognosis of patients suspected of chronic coronary syndromes.
引用
收藏
页码:645 / 654
页数:10
相关论文